000			01747 a2200505 4500
005			20250513234817.0
264		0	_c20010503
008			200105s 0 0 eng d
022			_a0003-987X
040			_aNLM _beng _cNLM
100	1		_aYosipovitch, G
245	0	0	_aSuggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. _h[electronic resource]
260			_bArchives of dermatology _cApr 2001
300			_a477-81 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Review
650	0	4	_aAdult
650	0	4	_aAge Factors
650	0	4	_aAged
650	0	4	_aCalcitonin _xtherapeutic use
650	0	4	_aCalcium _xtherapeutic use
650	0	4	_aControlled Clinical Trials as Topic
650	0	4	_aDensitometry
650	0	4	_aDiphosphonates _xtherapeutic use
650	0	4	_aEstrogen Replacement Therapy
650	0	4	_aEstrogens, Conjugated (USP) _xadministration & dosage
650	0	4	_aExercise
650	0	4	_aFemale
650	0	4	_aFractures, Bone _xprevention & control
650	0	4	_aGlucocorticoids _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMeta-Analysis as Topic
650	0	4	_aMiddle Aged
650	0	4	_aOsteoporosis _xchemically induced
650	0	4	_aOsteoporosis, Postmenopausal _xprevention & control
650	0	4	_aRaloxifene Hydrochloride _xtherapeutic use
650	0	4	_aRisk Factors
650	0	4	_aSelective Estrogen Receptor Modulators _xtherapeutic use
650	0	4	_aSkin Diseases _xdrug therapy
650	0	4	_aTime Factors
650	0	4	_aVitamin D _xtherapeutic use
700	1		_aHoon, T S
700	1		_aLeok, G C
773	0		_tArchives of dermatology _gvol. 137 _gno. 4 _gp. 477-81
999			_c11231063 _d11231063